The DOI matches its Crossref record; 312 of the 312 references it cites were found in a registry or an index.
NAFLD: Mechanisms, Treatments, and Biomarkers
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic-associated fatty liver disease (MAFLD), is one of the most common causes of liver diseases worldwide. NAFLD is growing in parallel with the obesity epidemic. No pharmacological treatment is available to treat NAFLD, specifically. The reason might be that NAFLD is a multi-factorial disease with an incomplete understanding of the mechanisms involved, an absence of accurate and inexpensive imaging tools, and lack of adequate non-invasive biomarkers. NAFLD consists of the accumulation of excess lipids in the liver, causing lipotoxicity that might progress to metabolic-associated steatohepatitis (NASH), liver fibrosis, and hepatocellular carcinoma. The mechanisms for the pathogenesis of NAFLD, current interventions in the management of the disease, and the role of sirtuins as potential targets for treatment are discussed here. In addition, the current diagnostic tools, and the role of non-coding RNAs as emerging diagnostic biomarkers are summarized. The availability of non-invasive biomarkers, and accurate and inexpensive non-invasive diagnosis tools are crucial in the detection of the early signs in the progression of NAFLD. This will expedite clinical trials and the validation of the emerging therapeutic treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–312 of 312
de Brito, O. M., & Scorrano, L. (2009) · Mitochondrion · doi:10.1016/j.mito.2009.02.005 · Cited by 158
Mitochondrial Roles and Cytoprotection in Chronic Liver Injury
Degli Esposti, D., Hamelin, J., Bosselut, N., Saffroy, R., Sebagh, M., Pommier, A., Martel, C., & Lemoine, A. (2012) · Biochemistry Research International · doi:10.1155/2012/387626 · Cited by 158
Liu, J., Han, L., Zhu, L., & Yu, Y. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0194-7 · Cited by 158
SIRT3 is regulated by nutrient excess and modulates hepatic susceptibility to lipotoxicity
Bao, J., Scott, I., Lu, Z., Pang, L., Dimond, C. C., Gius, D., & Sack, M. N. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.07.009 · Cited by 157
Thyroid hormone (T3) and TRβ agonist GC‐1 inhibit/reverse nonalcoholic fatty liver in rats
Perra, A., Simbula, G., Simbula, M., Pibiri, M., Kowalik, M. A., Sulas, P., Cocco, M. T., Ledda‐Columbano, G. M., & Columbano, A. (2008) · The FASEB Journal · doi:10.1096/fj.08-108464 · Cited by 155
Mitochondria-Associated ER Membranes – The Origin Site of Autophagy
Yang, M., Li, C., Yang, S., Xiao, Y., Xiong, X., Chen, W., Zhao, H., Zhang, Q., Han, Y., & Sun, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00595 · Cited by 154
Poynard, T., Lassailly, G., Diaz, E., Clément, K., Caiazzo, R. J., Tordjman, J., Munteanu, M., Perazzo, H., Demol, B., Callafe, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030325 · Cited by 153
Are Lifestyle Therapies Effective for NAFLD Treatment?
El-Agroudy, N. N., Kurzbach, A., Rodionov, R. N., O’Sullivan, J., Roden, M., Birkenfeld, A. L., & Pesta, D. H. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.07.013 · Cited by 152
Glycerophosphate/Acylglycerophosphate Acyltransferases
Yamashita, A., Hayashi, Y., Matsumoto, N., Nemoto‐Sasaki, Y., Oka, S., Tanikawa, T., & Sugiura, T. (2014) · Biology · doi:10.3390/biology3040801 · Cited by 148
Regulation and Functions of Autophagic Lipolysis
Cingolani, F., & Czaja, M. J. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.06.003 · Cited by 148
SITES OF INITIAL REMOVAL OF CHYLOMICRON TRIGLYCERIDE FATTY ACIDS FROM THE BLOOD*
Nestel, P. J., Havel, R. J., & Bezman, A. (1962) · Journal of Clinical Investigation · doi:10.1172/jci104648 · Cited by 145
Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease
Abenavoli, L., Larussa, T., Corea, A., Procopio, A. C., Boccuto, L., Dallio, M., Federico, A., & Luzza, F. (2021) · Nutrients · doi:10.3390/nu13020494 · Cited by 145
Mitochondria in nonalcoholic fatty liver disease
Caldwell, S. H., Chang, C., Nakamoto, R. K., & Krugner-Higby, L. A. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.009 · Cited by 144
A Fad too Far? Dietary Strategies for the Prevention and Treatment of NAFLD
Moore, M. P., Cunningham, R. P., Dashek, R. J., Mucinski, J. M., & Rector, R. S. (2020) · Obesity · doi:10.1002/oby.22964 · Cited by 142
Wu, T., Liu, Y., Fu, Y., Liu, X., & Zhou, X.-H. (2014) · PubMed · Cited by 140
Gluchowski, N. L., Gabriel, K. R., Chitraju, C., Bronson, R. T., Mejhert, N., Boland, S., Wang, K., Lai, Z. W., Farese, R. V., & Walther, T. C. (2019) · Hepatology · doi:10.1002/hep.30765 · Cited by 138
Turpin-Nolan, S. M., Hoy, A. J., Brown, R. D., Rudaz, C. G., Honeyman, J. E., Matzaris, M., & Watt, M. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1895-5 · Cited by 137
Krammer, J., Digel, M., Ehehalt, F., Stremmel, W., Füllekrug, J., & Ehehalt, R. (2011) · International Journal of Medical Sciences · doi:10.7150/ijms.8.599 · Cited by 136
Sirtuins and nonalcoholic fatty liver disease
Nassir, F., & Ibdah, J. A. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i46.10084 · Cited by 135
Self-citationWang, R., Li, C., & Deng, C. (2010) · International Journal of Biological Sciences · doi:10.7150/ijbs.6.682 · Cited by 133
Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe?
Chen, J., Deng, X., Liu, Y., Tan, Q., Huang, G., Che, Q., Guo, J., & Su, Z. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.47143 · Cited by 132
Mitochondrial Dynamics in Adult Cardiomyocytes and Heart Diseases
Li, A., Gao, M., Jiang, W., Qin, Y. H., & Gong, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.584800 · Cited by 131
Ogiwara, H., Tanabe, T., Nikawa, J., et al. (1978) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1978.tb20893.x · Cited by 127
He, J., Hu, B., Shi, X., Weidert, E. R., Lu, P., Xu, M., Huang, M., Kelley, E. E., & Xie, W. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01658-12 · Cited by 126
Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD)
Jampoka, K., Muangpaisarn, P., Khongnomnan, K., Treeprasertsuk, S., Tangkijvanich, P., & Payungporn, S. (2018) · MicroRNA · doi:10.2174/2211536607666180531093302 · Cited by 126
Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients
Mariani, S., Fiore, D., Basciani, S., Persichetti, A., Contini, S., Lubrano, C., Salvatori, L., Lenzi, A., & Gnessi, L. (2014) · Endocrine · doi:10.1007/s12020-014-0465-x · Cited by 123
Mitochondrial oxidative function in NAFLD: Friend or foe?
Shum, M., Ngo, J., Shirihai, O. S., & Liesa, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101134 · Cited by 122
Role of aramchol in steatohepatitis and fibrosis in mice
Iruarrizaga‐Lejarreta, M., Varela‐Rey, M., Fernández‐Ramos, D., Martínez‐Arranz, I., Delgado, T. C., Simón, J., Juan, V. G., delaCruz‐Villar, L., Azkargorta, M., Lavín, J. L., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1107 · Cited by 120
Ciardullo, S., & Perseghin, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154752 · Cited by 120
Bao, J., Lu, Z., Joseph, J. J., Carabenciov, D., Dimond, C. C., Pang, L., Samsel, L., McCoy, J. P., Leclerc, J., Nguyen, P., et al. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22531 · Cited by 119
Exercise Combats Hepatic Steatosis: Potential Mechanisms and Clinical Implications
Thyfault, J. P., & Rector, R. S. (2020) · Diabetes · doi:10.2337/dbi18-0043 · Cited by 118
Shojaee-Moradie, F., Cuthbertson, D. J., Barrett, M., Jackson, N. C., Herring, R., Thomas, E. L., Bell, J., Kemp, G. J., Wright, J., & Umpleby, A. M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2353 · Cited by 116
Human Sirtuin Regulators: The “Success” Stories
Curry, A. M., White, D. S., Donu, D., & Cen, Y. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.752117 · Cited by 116
Nassir, F., Okunade, A. L., Brunt, E. M., & Abumrad, N. A. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m037812 · Cited by 115
Self-citationHepatic TM6SF2 Is Required for Lipidation of VLDL in a Pre-Golgi Compartment in Mice and Rats
Luo, F., Šmagris, Ē., Martin, S. A., do Vale, G. D., McDonald, J. G., Fletcher, J. A., Burgess, S. C., Hobbs, H. H., & Cohen, J. C. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.12.008 · Cited by 114
Liver‐Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer
Newberry, E. P., Hall, Z., Xie, Y., Molitor, E. A., Bayguinov, P. O., Strout, G. W., Fitzpatrick, J. A. J., Brunt, E. M., Griffin, J. L., & Davidson, N. O. (2021) · Hepatology · doi:10.1002/hep.31771 · Cited by 113
MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease
Fang, Z., Dou, G., & Wang, L. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59588 · Cited by 110
Tracing insights into de novo lipogenesis in liver and adipose tissues
Wallace, M., & Metallo, C. M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.02.012 · Cited by 107
Sheedfar, F., Sung, M. M. Y., Aparicio-Vergara, M., Kloosterhuis, N., Miquilena-Colina, M. E., Vargas‐Castrillón, J., Febbraio, M., Jacobs, R. L., de Bruin, A., Vinciguerra, M., et al. (2014) · Aging · doi:10.18632/aging.100652 · Cited by 105
The influence of dietary fatty acids on liver fat content and metabolism
Hodson, L., Rosqvist, F., & Parry, S. A. (2019) · Proceedings of The Nutrition Society · doi:10.1017/s0029665119000569 · Cited by 104
Martinou, E., Pericleous, M., Stefanova, I., Kaur, V., & Angelidi, A. M. (2022) · Diagnostics · doi:10.3390/diagnostics12020407 · Cited by 104
Fasting Energy Homeostasis in Mice with Adipose Deficiency of Desnutrin/Adipose Triglyceride Lipase
Wu, J. W., Wang, S. P., Casavant, S., Moreau, A., Yang, G. S., & Mitchell, G. A. (2012) · Endocrinology · doi:10.1210/en.2011-1518 · Cited by 103
Mitochondrial Dysfunction in the Transition from NASH to HCC
Léveillé, M., & Estall, J. L. (2019) · Metabolites · doi:10.3390/metabo9100233 · Cited by 100
Henriksson, E., & Andersen, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601349 · Cited by 100
Role of mitochondrial quality control in the pathogenesis of nonalcoholic fatty liver disease
Li, R., Toan, S., & Zhou, H. (2020) · Aging · doi:10.18632/aging.102972 · Cited by 98
FGF19 and FGF21: In NASH we trust
Talukdar, S., & Kharitonenkov, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101152 · Cited by 96
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 96
Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention
O’Gorman, P., Naimimohasses, S., Monaghan, A., Kennedy, M., Melo, A. M., Ní Fhloinn, D., Doherty, D. G., Beddy, P., Finn, S. P., Moore, J. B., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15989 · Cited by 94
Steneberg, P., Sykaras, A. G., Backlund, F., Straseviçiene, J., Söderström, I., & Edlund, H. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.640292 · Cited by 90
Alizadeh, E., Akbarzadeh, A., Eslaminejad, M. B., Barzegar, A., Hashemzadeh, S., Nejati‐Koshki, K., & Zarghami, N. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12398 · Cited by 88
Cefalu, A. B., Pirruccello, J. P., Noto, D., Gabriel, S., Valenti, V., Gupta, N., Spina, R., Tarugi, P., Kathiresan, S., & Averna, M. R. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.301101 · Cited by 86
Hepatic fatty acid partitioning
Hodson, L., & Frayn, K. N. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283462e16 · Cited by 84
Hannah, W. N., & Harrison, S. A. (2016) · Hepatology · doi:10.1002/hep.28699 · Cited by 83
Cyclophilin D Promotes Brain Mitochondrial F1FO ATP Synthase Dysfunction in Aging Mice
Gauba, E., Guo, L., & Du, H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160822 · Cited by 79
Oh, S., Tsujimoto, T., Kim, B., Uchida, F., Suzuki, H., Iizumi, S., Isobe, T., Sakae, T., Tanaka, K., & Shoda, J. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100253 · Cited by 77
Sendi, H., Mead, I., Wan, M., Mehrab‐Mohseni, M., Koch, K. L., Atala, A., Bonkovsky, H. L., & Bishop, C. E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200847 · Cited by 71
Thyroid hormone-mediated autophagy and mitochondrial turnover in NAFLD
Sinha, R. A., & Yen, P. M. (2016) · Cell & Bioscience · doi:10.1186/s13578-016-0113-7 · Cited by 68
Dual Role of MicroRNAs in NAFLD
Ceccarelli, S., Panera, N., Gnani, D., & Nobili, V. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14048437 · Cited by 67
Ding, L., Li, Y., Wang, S., Wang, X.-S., Fang, F., Wang, W.-Y., Lv, P., Zhao, D., Feng, W., & Qi, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101617 · Cited by 65
Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers
Khalifa, O., Errafii, K., Al-Akl, N. S., & Arredouani, A. (2020) · Disease Markers · doi:10.1155/2020/8822859 · Cited by 65
Emerging Therapies for Liver Fibrosis
Fowell, A. J., & Iredale, J. P. (2006) · Digestive Diseases · doi:10.1159/000090320 · Cited by 64
MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease
Panera, N., Gnani, D., Crudele, A., Ceccarelli, S., Nobili, V., & Alisi, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15079 · Cited by 63
Enooku, K., Tsutsumi, T., Kondo, M., Fujiwara, N., Sasako, T., Shibahara, J., Kado, A., Okushin, K., Fujinaga, H., Nakagomi, R., et al. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01633-2 · Cited by 62
NAD+ and NAFLD – caution, causality and careful optimism
Dall, M., Hassing, A. S., & Treebak, J. T. (2021) · The Journal of Physiology · doi:10.1113/jp280908 · Cited by 61
Hanson, A., Wilhelmsen, D., & DiStefano, J. K. (2018) · Non-Coding RNA · doi:10.3390/ncrna4030018 · Cited by 60
Dangerous Liaisons: Mitochondrial DNA Meets the NLRP3 Inflammasome
Martinon, F. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.005 · Cited by 57
Negrete, L. M., Middleton, M. S., Clark, L., Wolfson, T. J., Gamst, A. C., Lam, J., Changchien, C., Deyoung-Dominguez, I. M., Hamilton, G., Loomba, R. S., et al. (2013) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24284 · Cited by 57
Regulation of mitochondrial trifunctional protein modulates nonalcoholic fatty liver disease in mice
Nassir, F., Arndt, J. J., Johnson, S. A., & Ibdah, J. A. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m080952 · Cited by 57
Self-citationGonzález-Paredes, F. J., Mesa, G. H., Arráez, D. E. M., Reyes, R. M., Abrante, B., Díaz-Flores, F., SALIDO, E. C., Quintero, E., & Hernández‐Guerra, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156650 · Cited by 56
Discordant hepatic fatty acid oxidation and triglyceride hydrolysis leads to liver disease
Alpergin, E. S. S., Choi, J., & Wolfgang, M. J. (2021) · JCI Insight · doi:10.1172/jci.insight.135626 · Cited by 56
Bass, N. M. (1990) · Molecular and Cellular Biochemistry · doi:10.1007/bf00231381 · Cited by 55
Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
Noureddin, M., Muthiah, M. D., & Sanyal, A. J. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.105 · Cited by 55
Jakubczyk, K., Skonieczna‐Żydecka, K., Kałduńska, J., Stachowska, E., Gutowska, I., & Janda, K. (2020) · Nutrients · doi:10.3390/nu12082435 · Cited by 55
Hepatic ATGL knockdown uncouples glucose intolerance from liver TAG accumulation
Ong, K. T., Mashek, M. T., Bu, S. Y., & Mashek, D. G. (2012) · The FASEB Journal · doi:10.1096/fj.12-213454 · Cited by 54
Siddiqui, M. S., Patidar, K. R., Boyett, S. L., Luketic, V. A., Puri, P., & Sanyal, A. J. (2015) · Liver International · doi:10.1111/liv.13054 · Cited by 54
Cheng, Y., Mai, J., Hou, T., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.04.065 · Cited by 54
Rieusset, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.097 · Cited by 53
Cioffi, F., Giacco, A., Petito, G., Matteis, R. D., Senese, R., Lombardi, A., de Lange, P., Moreno, M., Goglia, F., Lanni, A., et al. (2022) · Genes · doi:10.3390/genes13020315 · Cited by 53
Mea6 controls VLDL transport through the coordinated regulation of COPII assembly
Wang, Y., Liu, L., Zhang, H., Fan, J., Zhang, F., Yu, M., Shi, L., Yang, L., Lam, S. M., Wang, H., et al. (2016) · Cell Research · doi:10.1038/cr.2016.75 · Cited by 50
Akuta, N., Kawamura, Y., Suzuki, F., Saitoh, S., Arase, Y., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., Suzuki, Y., et al. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0557-6 · Cited by 50
Merry, T. L., Tran, M., Dodd, G. T., Mangiafico, S. P., Wiede, F., Kaur, S., McLean, C., Andrikopoulos, S., & Tiganis, T. (2016) · Diabetologia · doi:10.1007/s00125-016-4084-3 · Cited by 49
Barroso, E., Rodríguez‐Rodríguez, R., Zarei, M., Pizarro‐Delgado, J., Planavila, A., Palomer, X., Villarroya, F., & Vázquez‐Carrera, M. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00640-8 · Cited by 49
Circulating levels of miR‐122 and nonalcoholic fatty liver disease in pre‐pubertal obese children
Brandt, S., Roos, J., Inzaghi, E., Kotnik, P., Kovač, J., Battelino, T., Cianfarani, S., Nobili, V., Colajacomo, M., Kratzer, W., et al. (2017) · Pediatric Obesity · doi:10.1111/ijpo.12261 · Cited by 48
Peters, K. M., Wilson, R. B., & Borradaile, N. M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000535 · Cited by 48
Braza-Boïls, A., Marí-Alexandre, J., Molina, P., Arnau, M., Barceló-Molina, M., Domingo, D., Girbés, J., Giner, J., Martínez-Dolz, L., & Zorio, E. (2016) · Liver international (Print) · doi:10.1111/liv.13097 · Cited by 47
Fu, N., Niu, X., Wang, Y., Du, H., Wang, B., Du, J., Li, Y., Wang, R., Zhang, Y., Zhao, S., et al. (2016) · PubMed · Cited by 47
Cheng, J., Liu, C., Hu, K., Greenberg, A. S., Wu, D., Ausman, L. M., McBurney, M. W., & Wang, X. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.004 · Cited by 47
MiR-181b regulates steatosis in nonalcoholic fatty liver disease via targeting SIRT1
Wang, Y., Zhu, K., Yu, W., Wang, H., Liu, L., Wu, Q., Li, S., & Guo, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.042 · Cited by 47
Krishnasamy, Y., Gooz, M. B., Li, L., Lemasters, J. J., & Zhong, Z. (2019) · Europe PMC (PubMed Central) · Cited by 47
Lambrecht, J., & Tacke, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.634409 · Cited by 46
Bartesaghi, S., Wallenius, K., Hovdal, D., Liljeblad, M., Wallin, S., Dekker, N., Barlind, L., Davies, N. M., Seeliger, F., Winzell, M. S., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.010 · Cited by 44
Ren, T., Zhu, L., Shen, Y., Mou, Q., Lin, T., & Feng, H. (2019) · Food & Function · doi:10.1039/c8fo02298d · Cited by 43
Characterization of murine SIRT3 transcript variants and corresponding protein products
Yang, Y., Hubbard, B. P., Sinclair, D. A., & Tong, Q. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22795 · Cited by 40
Vecchione, G., Grasselli, E., Cioffi, F., Baldini, F., Oliveira, P. J., Sardão, V. A., Cortese, K., Lanni, A., Voci, A., Portincasa, P., et al. (2017) · Frontiers in Nutrition · doi:10.3389/fnut.2017.00042 · Cited by 40
Schmitz, S. M., Kroh, A., Ulmer, T. F., Andruszkow, J., Luedde, T., Brozat, J. F., Neumann, U. P., & Alizai, P. H. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01400-1 · Cited by 39
Hallsworth, K., McPherson, S., Anstee, Q. M., Flynn, D., Haigh, L., & Avery, L. (2020) · Journal of Medical Internet Research · doi:10.2196/20491 · Cited by 39
Tabibian, J. H., Lazo, M., Durazo, F. A., Yeh, H. C., Tong, M. J., & Clark, J. M. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06443.x · Cited by 36
Browning, M. G., Khoraki, J., DeAntonio, J. H., Mazzini, G. S., Mangino, M. J., Siddiqui, M. S., Wolfe, L. G., & Campos, G. M. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.309 · Cited by 36
Vranas, M., Yang, L., Rasool, S., Croteau, N., Krett, J. D., Sauvé, V., Gehring, K., Fon, E. A., Durcan, T. M., & Trempe, J. (2022) · Open Biology · doi:10.1098/rsob.210255 · Cited by 36
Banitalebi, E., Faramarzi, M., Nasiri, S., Ghahfarrokhi, M. M., & Rabiee, V. (2019) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2018.0086 · Cited by 35
Blocking mitochondrial cyclophilin D ameliorates TSH-impaired defensive barrier of artery
Liu, X., Du, H., Chai, Q., Jia, Q., Liu, L., Zhao, M., Li, J., Tang, H. R., Chen, W., Zhao, L., et al. (2018) · Redox Biology · doi:10.1016/j.redox.2018.01.004 · Cited by 33
Ali, A. H., Juboori, A. A., Petroski, G. F., Diaz‐Arias, A. A., Syed‐Abdul, M. M., Wheeler, A. A., Ganga, R., Pitt, J. B., Spencer, N., Hammoud, G. M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051201 · Cited by 33
Alkhouri, N., Tincopa, M. A., Loomba, R. S., & Harrison, S. A. (2021) · Hepatology Communications · doi:10.1002/hep4.1814 · Cited by 31
NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice
Xiong, X., Yu, J., Fan, R., Zhang, C., Xu, L., Sun, X., Huang, Y., Wang, Q., Ruan, H., & Qian, X. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212523 · Cited by 29
Qian, X., Zong, W., Ma, L., Yang, Z., Chen, W., Yan, J., & Xu, J. (2022) · Bioengineered · doi:10.1080/21655979.2022.2051815 · Cited by 28
Thyroid Stimulating Hormone Triggers Hepatic Mitochondrial Stress through Cyclophilin D Acetylation
Wang, X., Mao, J., Zhou, X., Li, Q., Gao, L., & Zhao, J. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1249630 · Cited by 27
Long Non-Coding RNAs Involved in Progression of Non-Alcoholic Fatty Liver Disease to Steatohepatitis
Atanasovska, B., Rensen, S. S., Marsman, G., Shiri‐Sverdlov, R., Withoff, S., Kuipers, F., Wijmenga, C., van de Sluis, B., & Fu, J. (2021) · Cells · doi:10.3390/cells10081883 · Cited by 27
Ünsal, İ. Ö., Çalapkulu, M., Sencar, M. E., Çakal, B., & Özbek, M. (2022) · Scientific Reports · doi:10.1038/s41598-021-04361-x · Cited by 25
Murine Sirt3 protein isoforms have variable half-lives
Yang, Y., Chen, K. Y., & Tong, Q. (2011) · Gene · doi:10.1016/j.gene.2011.07.029 · Cited by 18
Serra, J. T., Mueller, J. H., Teng, H., Elshaarawy, O., & Mueller, S. (2020) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s245455 · Cited by 16
Ciardullo, S., Ronchetti, C., Muraca, E., Oltolini, A., Perra, S., Bianconi, E., Zerbini, F., Cannistraci, R., Manzoni, G., Gastaldelli, A., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01188-7 · Cited by 14
Role of acetylation in nonalcoholic fatty liver disease: a focus on SIRT1 and SIRT3
Nassir, F. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00017 · Cited by 10
Self-citation
Cited by
Updated mechanisms of MASLD pathogenesis
Li, Y., Yang, P., Ye, J., Xu, Q., Wu, J., & Wang, Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02108-x · Cited by 300
LeFort, K. R., Rungratanawanich, W., & Song, B.-J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05061-7 · Cited by 202
Liao, C., Liang, X., Zhang, X., & Li, Y. (2023) · PLOS ONE · doi:10.1371/journal.pone.0289616 · Cited by 63
Frankowski, R., Kobierecki, M., Wittczak, A., Różycka-Kosmalska, M., Pietras, T., Sipowicz, K., & Kosmalski, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119677 · Cited by 58
Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study
Ditzenberger, G. L., Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Moser, C., Belaunzaran-Zamudio, P. F., Brown, T. T., Corey, K., Landay, A. L., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciae384 · Cited by 44
Metadata
- Authors
- Nassir, F.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2022-06-13
- Volume
- 12
- Issue
- 6
- Pages
- 824
- ISSN
- 2218-273X (ISSN-L)
- OpenAlex
- W4282838589
- Cited by
- 405
- References
- 312
- FWCI
- 49.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.